All In Biotech

Drug Trial Radar · NCT02117167

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 999 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

999

Actual

Start

Apr 23, 2014

Primary completion

Dec 22, 2018

Study completion Dec 2023

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC; AstraZeneca
First posted
Apr 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).

Conditions

  • Non-small Cell Lung Cancer Metastatic

Interventions

  • AZD2014Drug

    Target: m-TOR

  • AZD4547Drug

    Target: FGFR

  • AZD5363Drug

    Target: AKT

  • AZD8931Drug

    Target: HER2, EGFR

  • SelumetinibDrug

    Target: MEK

  • VandetanibDrug

    Target : VEGF, EGFR

  • Standard maintenance for squamous NSCLCDrug

  • PemetrexedDrug

    Standard maintenance for non squamous NSCLC

  • DurvalumabDrug

    Target: PD-L1

  • savolitinibDrug

    target : MET

  • OlaparibDrug

    target : PARP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival in the targeted drug arm compared to standard maintenance therapy armTime frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Henri Duffau

    Avignon, France

  • Centre Hospitalier Universitaire de Besancon - Hopital Jean Minjoz

    Besançon, France

  • Hôpital Avicenne

    Bobigny, France

  • Institut Bergonié

    Bordeaux, France

  • Hôpital Ambroise Paré

    Boulogne-Billancourt, France

  • Hospices Civils de Lyon- Hôpital Louis Pradel

    Bron, France

  • Centre François Baclesse

    Caen, France

  • CHU Caen

    Caen, France

  • Chu de Caen - Hopital Cote de Nacre

    Caen, France

  • Hôpital Louis Pasteur

    Chartres, France

  • centre Jean Perrin

    Clermont-Ferrand, France

  • CHU Clermont Ferrand - Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • Hopitaux Civils de Colmar

    Colmar, France

  • Centre Hopsitalier Intercommunal de Créteil

    Créteil, France

  • Centre Georges François Leclerc

    Dijon, France

  • CHU Grenoble

    Grenoble, France

  • Chd Vendee

    La Roche-sur-Yon, France

  • CH du Mans

    Le Mans, France

  • Centre Oscar Lambret

    Lille, France

  • CHRU de Lille

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Hôpital Nord

    Marseille, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut de cancérologie de l'Ouest

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Chr Orleans

    Orléans, France

  • AH-HP Hôpital Saint Louis

    Paris, France

  • AP-HP Hôpital Cochin

    Paris, France

  • AP-HP Hôpital Tenon

    Paris, France

  • Institut Curie

    Paris, France

  • Centre Hospitalier de Pau

    Pau, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Chru Strasbourg - Nouvel Hopital Civil

    Strasbourg, France

  • CHI de Toulon - Hôpital Sainte-Musse

    Toulon, France

  • CHU Toulouse -Hôpital Larrey

    Toulouse, France

  • Hôpital Bretonneau

    Tours, France

  • Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.